Article
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2016
Madore Jason, Strbenac Dario, Vilain Ricardo, Menzies Alexander M, Yang Jeen Y H, Thompson John F, Long Georgina V, Mann Graham J, Scolyer Richard A, Wilmott James S
Abstract excerpt
PURPOSE: Understanding why some melanomas test negative for PD-L1 by IHC may have implications for the application of anti-PD-1 therapies in melanoma management. This study sought to determine somatic mutation and gene expression patterns associated with tumor cell PD-L1 expression, or lack thereof, in stage III metastatic melanoma to better define therapeutically relevant patient subgroups. EXPERIMENTAL DESIGN:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.